Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and
accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone …

Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative
breast cancer (TNBC) accounting for 10–20% of cases. Historically, fewer treatment options …

The lack of effective therapies for metastatic triple‐negative breast cancer (mTNBC)
highlights the need for the development of novel treatment strategies. The cornerstone of …

Breast cancer is one of the most common malignant tumors in women in the world, and its
incidence is increasing year by year, which seriously threatens the physical and mental …

It is now standard of care to use neoadjuvant combination immunotherapy-chemotherapy in
patients with Stage 1 and 2 breast cancers. Chemo-immunotherapy combinations when …

Chemotherapy is the primary established systemic treatment for patients with triple-negative
breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of …

Triple negative breast cancer (TNBC) is still associated with grave prognosis, especially
compared to other breast cancer subtypes. Advances in medical science have improved our …

Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–
15% of all breast cancers and it is associated with a poor prognosis. However, recent new …

Triple-negative breast cancer (TNBC) refers to cancers that are low in expression of the
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Immunotherapy has become a mainstay of cancer treatment in many malignancies, though
its application in breast cancer remains limited. Of the breast cancer subtypes, triple …